SNDXSyndax Pharmaceuticals, Inc.
Is it safe?
Elevated bankruptcy risk: a balance sheet under strain and big price swings. Everything else is secondary until this clears.
Elevated financial-distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -79% · now 32% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can SNDX take a bad year?
Syndax Pharmaceuticals, Inc. holds $198M more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- -2.17
Altman Z-score · distress zone, below 1.8
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
Details›
- Total debtQ2 2026
- $350M
- Cash and short-term investments
- $548M
- Net cash
- $198M
- Operating profit, trailing twelve months
- −$194M
- Debt / equity
- 23.2×
- Annualised volatilitytwo years of daily moves
- 62%
- Worst drawdown on file
- −79%
- Below its 52-week high
- 32%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.